IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Clinical trial NCT06014528 · RECRUITING

Trial details

NCT number: NCT06014528
Sponsor: InxMed (Shanghai) Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Cancer Recurrent

Start date: 2022-09-06
Primary completion: 2026-12-24
Enrollment: 168

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.